# Feature Catalog: 100 Synergistic Features

**Version:** 1.0.0
**Last Updated:** December 29, 2025

---

## Category 1: Enhanced Disease Analyzers (Features 1-15)

### Feature 1: Dengue Fever Analyzer
**ID:** DISEASE-001
**Priority:** High
**Complexity:** Medium
**Dependencies:** Influenza analyzer framework

**Description:**
Implement drug resistance and immune escape prediction for all four Dengue virus serotypes (DENV-1 through DENV-4). Focus on NS1 antigenicity prediction for diagnostic sensitivity and NS3/NS5 for antiviral resistance.

**Rationale:**
- 390 million infections annually worldwide
- Antibody-dependent enhancement (ADE) makes cross-serotype immunity critical
- Reuses existing viral framework from influenza analyzer

**Technical Approach:**
- Extend `InfluenzaAnalyzer` base class
- Add serotype-specific mutation databases
- Implement ADE risk scoring based on cross-reactive epitopes
- NS3 protease inhibitor resistance (similar to HCV)
- NS5 polymerase inhibitor resistance

**Acceptance Criteria:**
- [ ] Support all 4 DENV serotypes
- [ ] NS1 antigenicity scoring
- [ ] ADE risk prediction
- [ ] >0.75 Spearman correlation on validation set
- [ ] 90%+ test coverage

---

### Feature 2: Zika Virus NS5 Resistance Analyzer
**ID:** DISEASE-002
**Priority:** High
**Complexity:** Medium
**Dependencies:** HCV NS5 framework, Feature 1

**Description:**
Predict resistance to Zika virus antivirals targeting the NS5 RNA-dependent RNA polymerase (RdRp). Transfer learning from HCV NS5B experience.

**Rationale:**
- Public health emergency pathogen
- Shares NS5 polymerase structure with HCV (exploitable transfer learning)
- Critical for pregnant women (microcephaly prevention)

**Technical Approach:**
- Transfer HCV NS5B resistance patterns
- Fine-tune on Zika-specific mutations
- Add congenital Zika syndrome risk markers
- Implement nucleoside analog resistance prediction

**Acceptance Criteria:**
- [ ] NS5 polymerase inhibitor resistance scoring
- [ ] Transfer from HCV achieves >0.70 correlation
- [ ] Sofosbuvir analog resistance detection
- [ ] Integration with dengue analyzer for differential diagnosis

---

### Feature 3: Norovirus Evolution Tracker
**ID:** DISEASE-003
**Priority:** Medium
**Complexity:** Medium
**Dependencies:** Influenza antigenic drift models

**Description:**
Track norovirus capsid VP1 evolution for vaccine strain selection and outbreak prediction. Apply influenza antigenic drift models to norovirus genogroups.

**Rationale:**
- Leading cause of acute gastroenteritis globally
- Rapid evolution similar to influenza
- No approved antivirals (vaccine development focus)

**Technical Approach:**
- Adapt influenza HA antigenic site framework to VP1 P2 domain
- Implement genogroup classification (GI, GII)
- Genotype prediction (GII.4 dominance tracking)
- Histo-blood group antigen (HBGA) binding prediction

**Acceptance Criteria:**
- [ ] VP1 P2 domain mutation tracking
- [ ] Genogroup/genotype classification
- [ ] HBGA binding affinity prediction
- [ ] Antigenic drift visualization

---

### Feature 4: HPV Vaccine Escape Predictor
**ID:** DISEASE-004
**Priority:** Medium
**Complexity:** Medium
**Dependencies:** Cancer EGFR framework

**Description:**
Predict HPV L1 capsid mutations that may escape vaccine-induced immunity. Focus on high-risk types (HPV-16, HPV-18) and cross-protection assessment.

**Rationale:**
- Cervical cancer prevention critical
- Vaccine escape would have major public health impact
- L1 capsid structure amenable to p-adic analysis

**Technical Approach:**
- Map L1 capsid surface epitopes
- Predict neutralizing antibody escape mutations
- Cross-reactivity scoring between HPV types
- Integration with oncogenic transformation markers

**Acceptance Criteria:**
- [ ] HPV-16 and HPV-18 L1 analysis
- [ ] Vaccine escape mutation flagging
- [ ] Cross-protection prediction matrix
- [ ] Oncogenic risk integration

---

### Feature 5: Lyme Disease (Borrelia) Resistance Analyzer
**ID:** DISEASE-005
**Priority:** Medium
**Complexity:** High
**Dependencies:** TB framework for spirochete-specific adaptations

**Description:**
Predict antibiotic resistance in Borrelia burgdorferi and related species. Focus on doxycycline, amoxicillin, and ceftriaxone resistance mechanisms.

**Rationale:**
- Expanding geographic range due to climate change
- Treatment failure in late-stage disease
- Post-treatment Lyme disease syndrome understanding

**Technical Approach:**
- Adapt TB rifamycin resistance framework to Borrelia rpoB
- OspC serotype classification
- Persistent infection marker identification
- Multi-species support (B. burgdorferi, B. afzelii, B. garinii)

**Acceptance Criteria:**
- [ ] Antibiotic resistance scoring
- [ ] OspC serotyping
- [ ] Multi-species support
- [ ] Geographic strain tracking

---

### Feature 6: Leishmania Drug Resistance Analyzer
**ID:** DISEASE-006
**Priority:** Medium
**Complexity:** High
**Dependencies:** Malaria K13 framework

**Description:**
Predict drug resistance in Leishmania species for miltefosine, antimonials, amphotericin B, and paromomycin.

**Rationale:**
- 700,000-1 million new cases annually
- Miltefosine resistance emerging
- Transfer learning opportunity from Malaria parasite framework

**Technical Approach:**
- Extend Malaria K13 framework for kinetoplastid parasites
- Miltefosine transporter (MT) mutation database
- Antimony resistance (AQP1, MRPA genes)
- Species-specific models (L. donovani, L. major, L. braziliensis)

**Acceptance Criteria:**
- [ ] Multi-drug resistance scoring
- [ ] Species identification
- [ ] Treatment recommendation engine
- [ ] >0.70 correlation on available datasets

---

### Feature 7: Trypanosoma (Sleeping Sickness) Analyzer
**ID:** DISEASE-007
**Priority:** Low
**Complexity:** High
**Dependencies:** Feature 6, Malaria framework

**Description:**
Predict drug resistance in Trypanosoma brucei for pentamidine, suramin, melarsoprol, eflornithine, and fexinidazole.

**Rationale:**
- Neglected tropical disease
- Drug resistance threatens elimination goals
- Shares kinetoplastid biology with Leishmania

**Technical Approach:**
- Shared kinetoplastid framework with Leishmania
- P2 adenosine transporter (TbAT1) mutations
- Aquaglyceroporin mutations
- Stage-specific treatment recommendations

**Acceptance Criteria:**
- [ ] Multi-drug resistance prediction
- [ ] Stage 1 vs Stage 2 disease markers
- [ ] Fexinidazole susceptibility scoring
- [ ] Integration with Leishmania analyzer

---

### Feature 8: Clostridioides difficile Resistance Analyzer
**ID:** DISEASE-008
**Priority:** High
**Complexity:** Medium
**Dependencies:** MRSA MDR framework

**Description:**
Predict antibiotic resistance and hypervirulent strain detection for C. difficile. Focus on vancomycin, metronidazole, and fidaxomicin.

**Rationale:**
- 500,000 US infections annually
- Recurrent infection major clinical challenge
- Hypervirulent strains (ribotype 027) spreading

**Technical Approach:**
- Adapt MRSA MDR framework
- Fluoroquinolone resistance (gyrA/gyrB)
- Fidaxomicin resistance (rpoB)
- Toxin gene (tcdA/tcdB) variant detection
- Ribotype classification

**Acceptance Criteria:**
- [ ] Multi-drug resistance scoring
- [ ] Hypervirulent strain flagging (027, 078)
- [ ] Recurrence risk prediction
- [ ] Toxin variant detection

---

### Feature 9: Neisseria gonorrhoeae MDR Analyzer
**ID:** DISEASE-009
**Priority:** High
**Complexity:** Medium
**Dependencies:** TB cephalosporin mechanisms

**Description:**
Predict multi-drug resistance in N. gonorrhoeae with focus on ceftriaxone (last-line therapy) and emerging azithromycin resistance.

**Rationale:**
- WHO priority pathogen
- XDR strains emerging globally
- Public health emergency potential

**Technical Approach:**
- penA mosaic allele detection
- mtrR efflux pump mutations
- 23S rRNA azithromycin resistance
- Ceftriaxone MIC prediction

**Acceptance Criteria:**
- [ ] Ceftriaxone resistance prediction
- [ ] Azithromycin resistance scoring
- [ ] XDR strain flagging
- [ ] MIC prediction accuracy <1 dilution

---

### Feature 10: Enterococcus VRE Analyzer
**ID:** DISEASE-010
**Priority:** High
**Complexity:** Medium
**Dependencies:** MRSA vanA/vanB detection framework

**Description:**
Predict vancomycin resistance in Enterococcus faecium and E. faecalis. Detect vanA, vanB, and other van operons.

**Rationale:**
- Top 5 hospital-acquired pathogen
- Limited treatment options for VRE
- Daptomycin and linezolid resistance emerging

**Technical Approach:**
- Extend MRSA framework for van operons
- vanA vs vanB phenotype prediction
- Daptomycin resistance (liaFSR mutations)
- Linezolid resistance (cfr, optrA, 23S rRNA)

**Acceptance Criteria:**
- [ ] van operon classification
- [ ] Multi-drug resistance profiling
- [ ] Species differentiation (E. faecium vs E. faecalis)
- [ ] Treatment recommendation engine

---

### Feature 11: Acinetobacter baumannii MDR Analyzer
**ID:** DISEASE-011
**Priority:** High
**Complexity:** High
**Dependencies:** MRSA pan-resistance framework

**Description:**
Predict multi-drug and pan-drug resistance in A. baumannii. Critical for ICU settings and military/trauma medicine.

**Rationale:**
- CDC urgent threat pathogen
- Pan-drug resistance occurring
- Carbapenem resistance widespread

**Technical Approach:**
- OXA carbapenemase detection (OXA-23, OXA-24, OXA-58)
- Colistin resistance (pmrABC, lpxACD)
- Tigecycline resistance (adeABC efflux)
- ISAba1 insertion sequence tracking

**Acceptance Criteria:**
- [ ] Carbapenemase typing
- [ ] Colistin susceptibility prediction
- [ ] Pan-drug resistance flagging
- [ ] Outbreak clone detection

---

### Feature 12: Pseudomonas aeruginosa MDR Analyzer
**ID:** DISEASE-012
**Priority:** High
**Complexity:** High
**Dependencies:** TB multi-mechanism model

**Description:**
Predict resistance across multiple mechanisms in P. aeruginosa: efflux pumps, porins, beta-lactamases, and target modifications.

**Rationale:**
- Cystic fibrosis major pathogen
- Intrinsic resistance mechanisms
- Biofilm formation complicates treatment

**Technical Approach:**
- MexAB-OprM efflux pump mutations
- OprD porin loss detection
- AmpC overexpression prediction
- MBL detection (VIM, IMP, NDM)

**Acceptance Criteria:**
- [ ] Multi-mechanism resistance profiling
- [ ] Cystic fibrosis isolate support
- [ ] Biofilm-associated resistance markers
- [ ] Carbapenemase detection

---

### Feature 13: Klebsiella pneumoniae Carbapenemase Analyzer
**ID:** DISEASE-013
**Priority:** High
**Complexity:** Medium
**Dependencies:** TB patterns, Features 11-12

**Description:**
Detect and characterize carbapenemase-producing K. pneumoniae (KPC, NDM, OXA-48). Critical for infection control.

**Rationale:**
- CRE (carbapenem-resistant Enterobacteriaceae) epidemic
- KPC spreading globally
- Mortality >40% in bloodstream infections

**Technical Approach:**
- KPC variant typing (KPC-2, KPC-3)
- NDM variant detection
- OXA-48-like enzyme identification
- Plasmid-mediated resistance tracking

**Acceptance Criteria:**
- [ ] Carbapenemase classification
- [ ] Variant-level typing
- [ ] MIC prediction
- [ ] Infection control alerts

---

### Feature 14: Salmonella typhi XDR Analyzer
**ID:** DISEASE-014
**Priority:** Medium
**Complexity:** Medium
**Dependencies:** TB XDR classification framework

**Description:**
Detect extensively drug-resistant (XDR) typhoid fever strains. Critical for South Asia outbreak response.

**Rationale:**
- XDR typhoid outbreak ongoing (Pakistan)
- Azithromycin last oral option
- Vaccine escape potential

**Technical Approach:**
- Apply TB XDR classification logic
- qnrS fluoroquinolone resistance
- ESBL detection (blaCTX-M-15)
- Azithromycin resistance (acrB mutations)

**Acceptance Criteria:**
- [ ] XDR classification
- [ ] Treatment option enumeration
- [ ] Outbreak strain typing
- [ ] Vaccine strain comparison

---

### Feature 15: Aspergillus fumigatus Azole Resistance Analyzer
**ID:** DISEASE-015
**Priority:** Medium
**Complexity:** Medium
**Dependencies:** Candida azole resistance framework

**Description:**
Predict azole resistance in A. fumigatus for invasive aspergillosis treatment. Focus on environmental azole resistance from agricultural fungicide use.

**Rationale:**
- Increasing resistance from agricultural azoles
- Invasive aspergillosis mortality >50%
- Immunocompromised patient protection

**Technical Approach:**
- Extend Candida framework to cyp51A mutations
- TR34/L98H tandem repeat detection
- TR46/Y121F/T289A detection
- Cross-resistance profiling (voriconazole, itraconazole, posaconazole)

**Acceptance Criteria:**
- [ ] cyp51A mutation database
- [ ] TR mutation detection
- [ ] Cross-resistance matrix
- [ ] Environmental vs clinical origin classification

---

## Category 2: Novel Encoding Methods (Features 16-25)

### Feature 16: 5-adic Amino Acid Encoder
**ID:** ENCODE-001
**Priority:** High
**Complexity:** Medium
**Dependencies:** Existing 3-adic codon encoder

**Description:**
Extend p-adic encoding from 3-adic (codons) to 5-adic for the 20 standard amino acids. Prime 5 provides natural grouping for amino acid properties.

**Rationale:**
- 20 amino acids don't map cleanly to prime 3
- 5-adic provides 5^3 = 125 positions (sufficient for 20 AA + modifications)
- Hierarchical: hydrophobic/polar/charged → specific AA

**Technical Approach:**
- Define 5-adic amino acid hierarchy based on physicochemical properties
- Level 0: Overall class (hydrophobic, polar, charged+, charged-, special)
- Level 1: Subclass (aliphatic, aromatic, hydroxyl, etc.)
- Level 2: Specific amino acid
- Implement `FiveAdicEncoder` class extending `PAdicEncoder`

**Acceptance Criteria:**
- [ ] 5-adic embedding for all 20 standard amino acids
- [ ] Physicochemical property preservation
- [ ] Improved performance on amino acid-level predictions
- [ ] Integration with existing 3-adic codon encoder

---

### Feature 17: 7-adic Secondary Structure Encoder
**ID:** ENCODE-002
**Priority:** Medium
**Complexity:** Medium
**Dependencies:** Feature 16, AlphaFold integration

**Description:**
Encode protein secondary structure (helix, sheet, coil, turn, bend, bridge, unstructured) using prime 7.

**Rationale:**
- 7 standard secondary structure states (DSSP)
- P-adic hierarchy can capture structural transitions
- Complements AlphaFold structure predictions

**Technical Approach:**
- Map DSSP 8-state to 7-adic representation
- Encode local structural context
- Capture helix-sheet transitions
- Integration with SE(3) equivariant encoder

**Acceptance Criteria:**
- [ ] DSSP state encoding
- [ ] Context window support
- [ ] AlphaFold pLDDT weighting
- [ ] Improved structure-aware predictions

---

### Feature 18: Multi-prime Hierarchical Encoding
**ID:** ENCODE-003
**Priority:** High
**Complexity:** High
**Dependencies:** Features 16, 17, existing 3-adic

**Description:**
Combine multiple p-adic encodings (2-adic for purines/pyrimidines, 3-adic for codons, 5-adic for amino acids, 7-adic for structure) into unified hierarchical representation.

**Rationale:**
- Different biological scales require different primes
- Hierarchical encoding captures multi-scale information
- Novel contribution to computational biology

**Technical Approach:**
- Define product space: Z_2 × Z_3 × Z_5 × Z_7
- Implement multi-prime embedding layer
- Fusion mechanism for combined representation
- Learnable prime importance weights

**Acceptance Criteria:**
- [ ] Unified multi-prime encoder
- [ ] Learnable fusion weights
- [ ] Ablation study showing improvement
- [ ] Publication-ready methodology

---

### Feature 19: P-adic Protein Domain Encoder
**ID:** ENCODE-004
**Priority:** Medium
**Complexity:** High
**Dependencies:** Feature 18, Pfam/InterPro integration

**Description:**
Encode protein domain architecture using p-adic hierarchy: domain → motif → residue.

**Rationale:**
- Domain architecture determines function
- Hierarchical structure natural for p-adic
- Drug binding often domain-specific

**Technical Approach:**
- Pfam domain database integration
- Domain composition encoding
- Inter-domain interaction modeling
- Domain boundary uncertainty handling

**Acceptance Criteria:**
- [ ] Pfam domain encoding
- [ ] Multi-domain protein support
- [ ] Domain-specific resistance prediction
- [ ] Linker region handling

---

### Feature 20: Quaternary Structure P-adic Encoder
**ID:** ENCODE-005
**Priority:** Low
**Complexity:** High
**Dependencies:** Feature 19, AlphaFold-Multimer

**Description:**
Encode protein complex assembly and subunit interactions using p-adic representation.

**Rationale:**
- Many drug targets are protein complexes
- Resistance can affect complex assembly
- AlphaFold-Multimer provides structural basis

**Technical Approach:**
- Subunit composition encoding
- Interface residue identification
- Symmetry group encoding
- Assembly pathway representation

**Acceptance Criteria:**
- [ ] Homo/hetero-oligomer support
- [ ] Interface residue encoding
- [ ] Assembly defect prediction
- [ ] Integration with AlphaFold-Multimer

---

### Feature 21: Glycan Shield P-adic Encoder
**ID:** ENCODE-006
**Priority:** Medium
**Complexity:** High
**Dependencies:** HIV analyzer glycan positions

**Description:**
Encode N-linked glycosylation sites and glycan shield composition using p-adic structure.

**Rationale:**
- Glycan shield critical for immune evasion (HIV, Influenza)
- N-X-S/T sequon detection
- Shield holes predict vulnerable epitopes

**Technical Approach:**
- Sequon detection and classification
- Glycan occupancy prediction
- Shield coverage calculation
- Epitope exposure scoring

**Acceptance Criteria:**
- [ ] N-linked sequon detection
- [ ] Glycan occupancy prediction
- [ ] Shield hole identification
- [ ] Integration with HIV/influenza analyzers

---

### Feature 22: Post-Translational Modification Encoder
**ID:** ENCODE-007
**Priority:** Low
**Complexity:** Medium
**Dependencies:** Feature 16

**Description:**
Encode phosphorylation, acetylation, ubiquitination, and other PTM sites that affect drug binding.

**Rationale:**
- PTMs affect drug efficacy
- Kinase inhibitor resistance involves phosphorylation sites
- Cancer mutations often affect PTM sites

**Technical Approach:**
- PTM site prediction integration
- Modification state encoding
- Drug binding affinity impact
- Cancer-specific PTM profiling

**Acceptance Criteria:**
- [ ] Major PTM type support
- [ ] Site prediction integration
- [ ] Drug binding impact scoring
- [ ] Cancer analyzer integration

---

### Feature 23: RNA Secondary Structure Encoder
**ID:** ENCODE-008
**Priority:** Medium
**Complexity:** Medium
**Dependencies:** Feature 17 concepts

**Description:**
Encode RNA secondary structure (stem-loop, hairpin, pseudoknot) for RNA virus analysis and ribozyme studies.

**Rationale:**
- RNA structure affects drug binding (riboswitches)
- Viral RNA structures are drug targets
- siRNA/antisense design requires structure

**Technical Approach:**
- Vienna RNA package integration
- Stem-loop hierarchy encoding
- Pseudoknot handling
- Co-transcriptional folding consideration

**Acceptance Criteria:**
- [ ] Standard secondary structure encoding
- [ ] Pseudoknot support
- [ ] Integration with viral analyzers
- [ ] Drug binding site identification

---

### Feature 24: Codon Usage Bias Encoder
**ID:** ENCODE-009
**Priority:** Low
**Complexity:** Low
**Dependencies:** Existing 3-adic encoder

**Description:**
Encode species-specific codon usage bias to improve expression prediction and detect horizontal gene transfer.

**Rationale:**
- Codon bias affects expression levels
- Unusual bias indicates HGT or recent mutations
- Therapeutic protein optimization

**Technical Approach:**
- Species-specific codon tables
- Codon adaptation index (CAI)
- tRNA availability weighting
- HGT detection scoring

**Acceptance Criteria:**
- [ ] Species-specific bias encoding
- [ ] CAI calculation
- [ ] HGT detection alerts
- [ ] Expression optimization scoring

---

### Feature 25: Synonymous Mutation Distance Encoder
**ID:** ENCODE-010
**Priority:** Medium
**Complexity:** Low
**Dependencies:** Existing 3-adic encoder

**Description:**
Enhanced wobble position weighting in p-adic distance for synonymous mutation analysis.

**Rationale:**
- Synonymous mutations can affect splicing, stability
- Third position (wobble) has different evolutionary pressure
- Codon usage affects translation speed

**Technical Approach:**
- Position-weighted p-adic distance
- Wobble position de-emphasis option
- Synonymous vs non-synonymous classification
- dN/dS ratio integration

**Acceptance Criteria:**
- [ ] Position-specific weighting
- [ ] dN/dS calculation
- [ ] Selection pressure inference
- [ ] Integration with evolution module

---

## Category 3: Hyperbolic Geometry Extensions (Features 26-35)

### Feature 26: Multi-sheet Hyperbolic Latent Space
**ID:** HYPER-001
**Priority:** High
**Complexity:** High
**Dependencies:** Existing Poincaré ball implementation

**Description:**
Implement multiple hyperbolic sheets for separate embedding of drugs, sequences, and disease contexts.

**Rationale:**
- Different entity types have different hierarchical structures
- Cross-sheet attention for drug-sequence interactions
- Avoids crowding in single manifold

**Technical Approach:**
- Separate Poincaré balls for drugs, sequences, diseases
- Cross-manifold attention mechanism
- Shared boundary for interaction modeling
- Sheet-specific curvature learning

**Acceptance Criteria:**
- [ ] Multi-sheet implementation
- [ ] Cross-sheet attention
- [ ] Improved drug-sequence matching
- [ ] Visualization support

---

### Feature 27: Hyperbolic Attention Mechanism
**ID:** HYPER-002
**Priority:** High
**Complexity:** High
**Dependencies:** Feature 26, transformer architecture

**Description:**
Replace standard Euclidean self-attention with Möbius gyrovector operations for native hyperbolic attention.

**Rationale:**
- Standard attention distorts hyperbolic geometry
- Möbius operations preserve curvature
- Better modeling of hierarchical relationships

**Technical Approach:**
- Möbius addition for query-key computation
- Hyperbolic softmax normalization
- Geodesic attention weights
- Efficient parallel implementation

**Acceptance Criteria:**
- [ ] Möbius attention layer
- [ ] Numerical stability verification
- [ ] Performance improvement demonstration
- [ ] Compatible with existing encoder

---

### Feature 28: Phylogenetic Tree Embedding
**ID:** HYPER-003
**Priority:** Medium
**Complexity:** Medium
**Dependencies:** Existing hyperbolic space

**Description:**
Embed phylogenetic trees from BEAST/MrBayes directly into hyperbolic latent space.

**Rationale:**
- Phylogenies are naturally tree-like (hyperbolic)
- Existing tools produce tree posteriors
- Enables evolutionary context in predictions

**Technical Approach:**
- Newick/NEXUS tree parsing
- Branch length to hyperbolic distance mapping
- Tree posterior sampling integration
- Ancestral state reconstruction

**Acceptance Criteria:**
- [ ] Tree format parsing
- [ ] Embedding quality metrics
- [ ] Posterior integration
- [ ] Ancestral reconstruction

---

### Feature 29: Hyperbolic Contrastive Learning
**ID:** HYPER-004
**Priority:** High
**Complexity:** Medium
**Dependencies:** Features 26, 27

**Description:**
Implement contrastive learning loss in hyperbolic space for drug-mutation pair embeddings.

**Rationale:**
- Contrastive learning improves representations
- Hyperbolic space better for hierarchical contrasts
- Drug-mutation pairs have natural positive/negative structure

**Technical Approach:**
- Hyperbolic InfoNCE loss
- Geodesic distance-based similarity
- Hard negative mining in hyperbolic space
- Temperature-scaled hyperbolic softmax

**Acceptance Criteria:**
- [ ] Hyperbolic contrastive loss
- [ ] Hard negative mining
- [ ] Representation quality improvement
- [ ] Drug-mutation retrieval benchmark

---

### Feature 30: Curvature-Adaptive Networks
**ID:** HYPER-005
**Priority:** Medium
**Complexity:** High
**Dependencies:** All hyperbolic features

**Description:**
Learn optimal manifold curvature per disease rather than fixed curvature.

**Rationale:**
- Different diseases have different hierarchical depth
- Fixed curvature is suboptimal
- Learnable curvature improves embeddings

**Technical Approach:**
- Per-disease curvature parameters
- Curvature gradient computation
- Numerical stability for varying curvature
- Curvature visualization tools

**Acceptance Criteria:**
- [ ] Learnable curvature per disease
- [ ] Stable training across curvature range
- [ ] Curvature interpretation analysis
- [ ] Ablation showing improvement

---

### Feature 31: Mixed-Curvature Product Manifolds
**ID:** HYPER-006
**Priority:** Medium
**Complexity:** High
**Dependencies:** Feature 30

**Description:**
Combine Poincaré ball (negative curvature), Euclidean (zero), and spherical (positive) in product manifold.

**Rationale:**
- Some features are hierarchical (hyperbolic)
- Some are linear (Euclidean)
- Some are cyclical (spherical)

**Technical Approach:**
- Product manifold: H^n × R^m × S^k
- Dimension allocation learning
- Mixed curvature operations
- Riemannian optimization

**Acceptance Criteria:**
- [ ] Product manifold implementation
- [ ] Automatic dimension allocation
- [ ] Performance comparison vs single manifold
- [ ] Interpretability analysis

---

### Feature 32: Hyperbolic Normalizing Flows
**ID:** HYPER-007
**Priority:** Low
**Complexity:** Very High
**Dependencies:** All hyperbolic features

**Description:**
Implement normalizing flows on Poincaré ball for better latent distribution modeling.

**Rationale:**
- Standard VAE assumes Gaussian latent
- Hyperbolic space needs wrapped distributions
- Flows enable complex distributions

**Technical Approach:**
- Tangent space flows
- Exponential/logarithmic map flows
- Wrapped normal as base distribution
- Inverse flow computation

**Acceptance Criteria:**
- [ ] Hyperbolic flow implementation
- [ ] ELBO improvement
- [ ] Sample quality assessment
- [ ] Computational efficiency

---

### Feature 33: Lorentz Model Alternative
**ID:** HYPER-008
**Priority:** Medium
**Complexity:** Medium
**Dependencies:** Existing Poincaré implementation

**Description:**
Implement Lorentz (hyperboloid) model as numerically stable alternative to Poincaré ball.

**Rationale:**
- Poincaré ball has numerical issues near boundary
- Lorentz model more stable for large-scale
- Easy conversion between models

**Technical Approach:**
- Lorentz inner product implementation
- Lorentz distance computation
- Poincaré-Lorentz conversion
- Automatic model switching based on scale

**Acceptance Criteria:**
- [ ] Lorentz model implementation
- [ ] Numerical stability verification
- [ ] Equivalent representations
- [ ] Automatic fallback mechanism

---

### Feature 34: Hyperbolic Batch Normalization
**ID:** HYPER-009
**Priority:** Medium
**Complexity:** Medium
**Dependencies:** Hyperbolic encoder

**Description:**
Implement manifold-aware batch normalization that respects hyperbolic geometry.

**Rationale:**
- Standard BatchNorm breaks hyperbolic properties
- Manifold-aware normalization needed
- Training stability improvement

**Technical Approach:**
- Fréchet mean computation
- Tangent space normalization
- Learnable scale in tangent space
- Running statistics on manifold

**Acceptance Criteria:**
- [ ] Hyperbolic BatchNorm layer
- [ ] Training stability improvement
- [ ] Compatible with existing architecture
- [ ] Proper gradient flow

---

### Feature 35: Geodesic Pooling Layers
**ID:** HYPER-010
**Priority:** Low
**Complexity:** Medium
**Dependencies:** Hyperbolic encoder

**Description:**
Pool features along geodesic paths rather than Euclidean averages.

**Rationale:**
- Max/mean pooling distorts hyperbolic space
- Geodesic pooling preserves geometry
- Better hierarchical feature aggregation

**Technical Approach:**
- Geodesic midpoint computation
- Fréchet mean pooling
- Geodesic max pooling approximation
- Multi-scale geodesic pooling

**Acceptance Criteria:**
- [ ] Geodesic pooling layers
- [ ] Multiple pooling strategies
- [ ] Performance comparison
- [ ] Integration with encoder

---

## Category 4: Uncertainty & Calibration (Features 36-45)

### Feature 36: Conformal Prediction Intervals
**ID:** UNCERT-001
**Priority:** Very High
**Complexity:** Medium
**Dependencies:** Existing uncertainty module

**Description:**
Implement conformal prediction for distribution-free uncertainty quantification with guaranteed coverage.

**Rationale:**
- Current methods don't guarantee coverage
- Clinical applications need statistical guarantees
- Distribution-free (no assumptions)

**Technical Approach:**
- Split conformal prediction
- Conformalized quantile regression
- Adaptive conformal inference
- Coverage verification

**Acceptance Criteria:**
- [ ] Guaranteed coverage (e.g., 90%)
- [ ] Adaptive interval widths
- [ ] Efficient calibration set usage
- [ ] Clinical deployment ready

---

### Feature 37: Temperature Scaling per Drug
**ID:** UNCERT-002
**Priority:** High
**Complexity:** Low
**Dependencies:** Feature 36

**Description:**
Learn drug-specific temperature parameters for calibration rather than global temperature.

**Rationale:**
- Different drugs have different uncertainty profiles
- Global temperature suboptimal
- Drug-specific calibration improves reliability

**Technical Approach:**
- Per-drug temperature parameters
- Drug-group temperature sharing option
- Calibration loss per drug
- Temperature visualization

**Acceptance Criteria:**
- [ ] Per-drug temperatures
- [ ] Improved per-drug calibration
- [ ] Temperature interpretation
- [ ] Easy clinical configuration

---

### Feature 38: Expected Calibration Error Dashboard
**ID:** UNCERT-003
**Priority:** High
**Complexity:** Low
**Dependencies:** Features 36, 37

**Description:**
Real-time monitoring dashboard for uncertainty calibration across all disease modules.

**Rationale:**
- Calibration can drift over time
- Clinical systems need monitoring
- Early detection of calibration issues

**Technical Approach:**
- ECE/MCE computation pipeline
- Reliability diagram generation
- Drift detection alerts
- Historical calibration tracking

**Acceptance Criteria:**
- [ ] Real-time ECE monitoring
- [ ] Reliability diagrams
- [ ] Drift alerts
- [ ] Historical trends

---

### Feature 39: Selective Prediction Module
**ID:** UNCERT-004
**Priority:** High
**Complexity:** Medium
**Dependencies:** All uncertainty features

**Description:**
Abstain from prediction when uncertainty exceeds configurable threshold, with clinician escalation.

**Rationale:**
- Better to abstain than provide unreliable prediction
- Clinical workflows need escalation paths
- Configurable per deployment context

**Technical Approach:**
- Uncertainty threshold configuration
- Abstention rate tracking
- Escalation workflow integration
- Cost-sensitive abstention

**Acceptance Criteria:**
- [ ] Configurable thresholds
- [ ] Abstention logging
- [ ] Escalation hooks
- [ ] Coverage-accuracy tradeoff analysis

---

### Feature 40: Bayesian Neural Network Layers
**ID:** UNCERT-005
**Priority:** Medium
**Complexity:** High
**Dependencies:** Existing model architecture

**Description:**
Add Bayesian layers for weight uncertainty, particularly useful for rare mutation predictions.

**Rationale:**
- Point estimates overconfident for rare events
- Weight uncertainty captures model uncertainty
- Better for few-shot scenarios

**Technical Approach:**
- Variational inference for weights
- Local reparameterization trick
- Flipout for efficient sampling
- Sparse Bayesian layers for efficiency

**Acceptance Criteria:**
- [ ] Bayesian encoder layers
- [ ] Efficient training
- [ ] Rare mutation uncertainty improvement
- [ ] Computational overhead <2x

---

### Feature 41: Deep Ensemble with Diversity Loss
**ID:** UNCERT-006
**Priority:** Medium
**Complexity:** Medium
**Dependencies:** Existing ensemble method

**Description:**
Train ensembles with explicit diversity loss to ensure disagreement on uncertain regions.

**Rationale:**
- Standard ensembles may converge to similar solutions
- Diversity improves uncertainty quality
- Better coverage of prediction space

**Technical Approach:**
- Pairwise diversity loss
- Negative correlation learning
- Diverse initialization strategies
- Diversity-accuracy tradeoff tuning

**Acceptance Criteria:**
- [ ] Diversity loss implementation
- [ ] Improved disagreement on uncertain cases
- [ ] Maintained accuracy
- [ ] Ensemble size optimization

---

### Feature 42: Heteroscedastic Uncertainty
**ID:** UNCERT-007
**Priority:** Medium
**Complexity:** Medium
**Dependencies:** Feature 40

**Description:**
Model input-dependent noise (aleatoric uncertainty) that varies with sequence characteristics.

**Rationale:**
- Some sequences inherently more variable
- Constant noise assumption incorrect
- Better uncertainty decomposition

**Technical Approach:**
- Predict mean and variance jointly
- Variance network branch
- Heteroscedastic loss function
- Variance regularization

**Acceptance Criteria:**
- [ ] Input-dependent variance prediction
- [ ] Improved aleatoric estimates
- [ ] Stable training
- [ ] Clinical interpretation tools

---

### Feature 43: Out-of-Distribution Detection
**ID:** UNCERT-008
**Priority:** High
**Complexity:** Medium
**Dependencies:** All uncertainty features

**Description:**
Flag sequences that are significantly different from training distribution.

**Rationale:**
- Model unreliable on OOD data
- Novel sequences need flagging
- Prevents silent failures

**Technical Approach:**
- Latent space density estimation
- Mahalanobis distance
- Energy-based OOD scores
- Ensemble disagreement for OOD

**Acceptance Criteria:**
- [ ] OOD detection module
- [ ] Configurable sensitivity
- [ ] Integration with abstention
- [ ] False positive rate control

---

### Feature 44: Epistemic vs Aleatoric Dashboard
**ID:** UNCERT-009
**Priority:** Medium
**Complexity:** Low
**Dependencies:** Features 40, 42

**Description:**
Visual dashboard decomposing uncertainty into epistemic (model) and aleatoric (data) components for clinicians.

**Rationale:**
- Different uncertainty types have different implications
- Epistemic: need more data
- Aleatoric: inherent variability

**Technical Approach:**
- Decomposition visualization
- Clinical interpretation guides
- Action recommendations per type
- Historical decomposition trends

**Acceptance Criteria:**
- [ ] Clear visual decomposition
- [ ] Clinical language explanations
- [ ] Actionable recommendations
- [ ] Export capabilities

---

### Feature 45: Uncertainty-Weighted Loss
**ID:** UNCERT-010
**Priority:** Medium
**Complexity:** Medium
**Dependencies:** All uncertainty features

**Description:**
Focus training on high-uncertainty regions to improve calibration where it matters most.

**Rationale:**
- Uniform training inefficient
- Uncertain regions need more attention
- Improves worst-case performance

**Technical Approach:**
- Uncertainty-weighted sampling
- Focal loss variant for uncertainty
- Curriculum based on uncertainty
- Dynamic weight adjustment

**Acceptance Criteria:**
- [ ] Uncertainty-weighted training
- [ ] Calibration improvement
- [ ] Maintained overall accuracy
- [ ] Training efficiency

---

## Category 5: Transfer Learning Enhancements (Features 46-55)

### Feature 46: Domain Adversarial Transfer
**ID:** TRANSFER-001
**Priority:** Very High
**Complexity:** High
**Dependencies:** Existing transfer pipeline

**Description:**
Learn disease-agnostic encoder via gradient reversal layer (GRL) for better cross-disease transfer.

**Rationale:**
- Current transfer still disease-specific
- Domain-invariant features transfer better
- Enables rare disease prediction

**Technical Approach:**
- Gradient reversal layer after encoder
- Domain classifier adversary
- Disease-invariant representation learning
- Progressive domain adaptation

**Acceptance Criteria:**
- [ ] GRL implementation
- [ ] Improved rare disease performance
- [ ] Domain-invariance verification
- [ ] Integration with existing pipeline

---

### Feature 47: Curriculum Transfer Learning
**ID:** TRANSFER-002
**Priority:** Medium
**Complexity:** Medium
**Dependencies:** Feature 46

**Description:**
Order source diseases by similarity to target for progressive transfer.

**Rationale:**
- Not all source diseases equally helpful
- Curriculum improves transfer efficiency
- Avoids negative transfer

**Technical Approach:**
- Disease similarity metrics
- Curriculum scheduling
- Progressive source addition
- Early stopping per source

**Acceptance Criteria:**
- [ ] Similarity metric computation
- [ ] Curriculum scheduler
- [ ] Improved transfer efficiency
- [ ] Negative transfer prevention

---

### Feature 48: Multi-Task Gradient Surgery
**ID:** TRANSFER-003
**Priority:** High
**Complexity:** High
**Dependencies:** Existing multi-task framework

**Description:**
Modify gradients to avoid conflicts between disease tasks (PCGrad, CAGrad).

**Rationale:**
- Multi-task gradients can conflict
- Gradient surgery resolves conflicts
- Better multi-disease training

**Technical Approach:**
- PCGrad: project conflicting gradients
- CAGrad: find common descent direction
- Gradient monitoring dashboard
- Dynamic conflict detection

**Acceptance Criteria:**
- [ ] PCGrad implementation
- [ ] Conflict detection
- [ ] Improved multi-disease training
- [ ] Gradient visualization

---

### Feature 49: Progressive Neural Network Transfer
**ID:** TRANSFER-004
**Priority:** Medium
**Complexity:** High
**Dependencies:** Feature 46

**Description:**
Add lateral connections from source disease columns to target disease column.

**Rationale:**
- Preserves source knowledge exactly
- Selective transfer via lateral connections
- No catastrophic forgetting

**Technical Approach:**
- Column architecture per disease
- Lateral adapters between columns
- Progressive column addition
- Memory-efficient implementation

**Acceptance Criteria:**
- [ ] Column architecture
- [ ] Lateral connections
- [ ] No forgetting verification
- [ ] Memory optimization

---

### Feature 50: Prototypical Networks for Rare Diseases
**ID:** TRANSFER-005
**Priority:** High
**Complexity:** Medium
**Dependencies:** Existing MAML framework

**Description:**
Few-shot learning via prototype matching for diseases with limited data.

**Rationale:**
- Some diseases have <100 sequences
- Prototypical networks efficient for few-shot
- Complements MAML

**Technical Approach:**
- Class prototype computation
- Distance-based classification
- Hyperbolic prototypes (synergy with hyperbolic space)
- Episode-based training

**Acceptance Criteria:**
- [ ] Prototype network implementation
- [ ] Hyperbolic prototype variant
- [ ] 5-shot performance benchmarks
- [ ] Integration with rare disease analyzers

---

### Feature 51: Self-Supervised Pre-training
**ID:** TRANSFER-006
**Priority:** Very High
**Complexity:** High
**Dependencies:** None (foundational)

**Description:**
Masked codon modeling (MCM) pre-training on billions of unlabeled sequences.

**Rationale:**
- Vast unlabeled sequence databases
- Self-supervised learning extremely effective
- Foundation model for all downstream tasks

**Technical Approach:**
- Codon-level masking (like BERT)
- 15% masking rate
- Pre-training on UniProt/NCBI
- Task-specific fine-tuning

**Acceptance Criteria:**
- [ ] MCM pre-training pipeline
- [ ] Large-scale data handling
- [ ] Fine-tuning protocols
- [ ] Performance improvement on all diseases

---

### Feature 52: Contrastive Pre-training
**ID:** TRANSFER-007
**Priority:** High
**Complexity:** Medium
**Dependencies:** Feature 51, Feature 29

**Description:**
P-adic distance-based contrastive pre-training loss.

**Rationale:**
- Complementary to MCM
- Leverages p-adic structure in pre-training
- Better sequence embeddings

**Technical Approach:**
- P-adic distance as similarity metric
- InfoNCE loss with p-adic augmentation
- Codon-level vs sequence-level contrastive
- Joint MCM + contrastive training

**Acceptance Criteria:**
- [ ] P-adic contrastive loss
- [ ] Pre-training pipeline
- [ ] Embedding quality metrics
- [ ] Downstream task improvement

---

### Feature 53: Cross-Domain Mixup
**ID:** TRANSFER-008
**Priority:** Medium
**Complexity:** Low
**Dependencies:** Existing multi-disease framework

**Description:**
Interpolate between disease domains for regularization and data augmentation.

**Rationale:**
- Mixup improves generalization
- Cross-domain mixup bridges diseases
- Simple implementation

**Technical Approach:**
- Sequence-level mixup
- Label smoothing
- Cross-disease pair sampling
- Mixup ratio scheduling

**Acceptance Criteria:**
- [ ] Cross-domain mixup implementation
- [ ] Improved generalization
- [ ] Optimal ratio finding
- [ ] Integration with training loop

---

### Feature 54: Elastic Weight Consolidation
**ID:** TRANSFER-009
**Priority:** Medium
**Complexity:** Medium
**Dependencies:** Sequential transfer scenarios

**Description:**
Prevent catastrophic forgetting when adding new diseases sequentially.

**Rationale:**
- Sequential disease addition is practical
- EWC preserves important weights
- Continual learning capability

**Technical Approach:**
- Fisher information computation
- Quadratic weight regularization
- Online EWC for multiple tasks
- Importance weight visualization

**Acceptance Criteria:**
- [ ] EWC implementation
- [ ] Forgetting prevention verification
- [ ] Sequential addition support
- [ ] Memory efficiency

---

### Feature 55: Knowledge Distillation Pipeline
**ID:** TRANSFER-010
**Priority:** High
**Complexity:** Medium
**Dependencies:** All transfer features

**Description:**
Compress multi-disease ensemble into single efficient model.

**Rationale:**
- Ensemble too large for deployment
- Distillation preserves performance
- Enables edge deployment

**Technical Approach:**
- Soft label distillation
- Feature distillation
- Progressive distillation
- Quantization-aware distillation

**Acceptance Criteria:**
- [ ] Distillation pipeline
- [ ] <10% performance loss
- [ ] 4x+ model compression
- [ ] Inference speed improvement

---

## Category 6: Architecture Innovations (Features 56-70)

### Feature 56: Hierarchical VAE
**ID:** ARCH-001
**Priority:** Very High
**Complexity:** High
**Dependencies:** Existing VAE architecture

**Description:**
Multi-level VAE: codon → gene → protein → organism hierarchy.

**Rationale:**
- Biological information is hierarchical
- Better latent disentanglement
- Matches p-adic encoding philosophy

**Technical Approach:**
- Stacked latent levels
- Top-down and bottom-up pathways
- Skip connections between levels
- Level-specific KL regularization

**Acceptance Criteria:**
- [ ] Multi-level architecture
- [ ] Hierarchical reconstruction
- [ ] Disentanglement metrics
- [ ] Biological interpretability

---

### Feature 57: VQ-VAE for Discrete Codons
**ID:** ARCH-002
**Priority:** High
**Complexity:** High
**Dependencies:** Feature 56

**Description:**
Vector-quantized VAE with learnable codon codebook.

**Rationale:**
- Codons are discrete, not continuous
- Codebook learns meaningful clusters
- Better reconstruction fidelity

**Technical Approach:**
- Discrete codebook learning
- Exponential moving average updates
- Commitment loss
- Codebook utilization optimization

**Acceptance Criteria:**
- [ ] VQ-VAE implementation
- [ ] Codebook analysis tools
- [ ] Improved discrete reconstruction
- [ ] Integration with p-adic encoder

---

### Feature 58: Conditional VAE
**ID:** ARCH-003
**Priority:** High
**Complexity:** Medium
**Dependencies:** Existing VAE

**Description:**
Condition generation on drug class, patient metadata, or disease context.

**Rationale:**
- Enable conditional generation
- Drug-specific sequence generation
- Patient-specific predictions

**Technical Approach:**
- Condition embedding layer
- Conditional prior
- Classifier-free guidance option
- Multi-condition support

**Acceptance Criteria:**
- [ ] CVAE implementation
- [ ] Drug-conditional generation
- [ ] Patient metadata conditioning
- [ ] Generation quality metrics

---

### Feature 59: β-VAE Disentanglement
**ID:** ARCH-004
**Priority:** Medium
**Complexity:** Low
**Dependencies:** Existing VAE

**Description:**
Disentangle drug resistance from fitness using β-VAE regularization.

**Rationale:**
- Resistance and fitness often conflated
- Disentanglement aids interpretation
- Better counterfactual analysis

**Technical Approach:**
- β parameter tuning
- Disentanglement metrics (DCI, MIG)
- Dimension-specific analysis
- β scheduling

**Acceptance Criteria:**
- [ ] β-VAE implementation
- [ ] Disentanglement metrics
- [ ] Interpretable dimensions
- [ ] Optimal β finding

---

### Feature 60: Sparse VAE
**ID:** ARCH-005
**Priority:** Low
**Complexity:** Medium
**Dependencies:** Feature 59

**Description:**
L1 regularization on latent for interpretable sparse representations.

**Rationale:**
- Dense latents hard to interpret
- Sparse latents identify key factors
- Feature selection in latent space

**Technical Approach:**
- L1 penalty on latent
- Spike-and-slab prior option
- Sparsity-accuracy tradeoff
- Feature importance ranking

**Acceptance Criteria:**
- [ ] Sparse VAE implementation
- [ ] Sparsity level control
- [ ] Feature importance extraction
- [ ] Biological interpretation

---

### Feature 61: Variational Transformer
**ID:** ARCH-006
**Priority:** High
**Complexity:** High
**Dependencies:** Existing encoder

**Description:**
Replace MLP encoder with transformer for better sequence modeling.

**Rationale:**
- Transformers excel at sequences
- Attention captures long-range dependencies
- Industry standard architecture

**Technical Approach:**
- Transformer encoder
- Variational bottleneck
- Position encodings (p-adic enhanced)
- Efficient attention variants

**Acceptance Criteria:**
- [ ] Transformer encoder integration
- [ ] Attention visualization
- [ ] Long sequence handling
- [ ] Computational efficiency

---

### Feature 62: Graph VAE for Protein Structure
**ID:** ARCH-007
**Priority:** Medium
**Complexity:** High
**Dependencies:** AlphaFold integration, SE(3) encoder

**Description:**
Graph neural network VAE operating on protein structure graphs.

**Rationale:**
- Protein structure is graph-like
- SE(3) equivariance for 3D
- Better structure-function learning

**Technical Approach:**
- SE(3)-equivariant GNN encoder
- Structure-aware latent
- Joint sequence-structure training
- AlphaFold predicted structure input

**Acceptance Criteria:**
- [ ] Graph VAE implementation
- [ ] SE(3) equivariance verification
- [ ] Structure reconstruction
- [ ] Improved structure-aware predictions

---

### Feature 63: Recurrent VAE for Sequences
**ID:** ARCH-008
**Priority:** Low
**Complexity:** Medium
**Dependencies:** Existing VAE

**Description:**
LSTM/GRU encoder for variable-length sequences without padding.

**Rationale:**
- Variable-length natural for sequences
- No padding artifacts
- Sequential generation capability

**Technical Approach:**
- Bidirectional LSTM encoder
- Sequential decoder
- Teacher forcing training
- Beam search generation

**Acceptance Criteria:**
- [ ] RNN VAE implementation
- [ ] Variable-length support
- [ ] Generation quality
- [ ] Comparison with transformer

---

### Feature 64: Flow-based Decoder
**ID:** ARCH-009
**Priority:** Medium
**Complexity:** High
**Dependencies:** Feature 32

**Description:**
Replace decoder with normalizing flow for invertible generation.

**Rationale:**
- Exact likelihood computation
- Invertible transformations
- Better generation quality

**Technical Approach:**
- RealNVP/Glow decoder
- Affine coupling layers
- Multi-scale architecture
- Latent-flow interface

**Acceptance Criteria:**
- [ ] Flow decoder implementation
- [ ] Generation quality metrics
- [ ] Likelihood computation
- [ ] Training stability

---

### Feature 65: Energy-Based Model Integration
**ID:** ARCH-010
**Priority:** Low
**Complexity:** High
**Dependencies:** Existing architecture

**Description:**
EBM for latent space refinement and out-of-distribution detection.

**Rationale:**
- EBMs define energy landscape
- Better density estimation
- OOD detection via energy

**Technical Approach:**
- Joint VAE-EBM training
- Langevin dynamics sampling
- Energy-based OOD scores
- Contrastive divergence training

**Acceptance Criteria:**
- [ ] EBM integration
- [ ] Improved latent quality
- [ ] OOD detection
- [ ] Stable training

---

### Feature 66: Diffusion-VAE Hybrid
**ID:** ARCH-011
**Priority:** Medium
**Complexity:** Very High
**Dependencies:** Existing diffusion module

**Description:**
Combine VAE latent structure with diffusion model decoder for generation.

**Rationale:**
- Diffusion generates high quality
- VAE provides structured latent
- Best of both approaches

**Technical Approach:**
- VAE encoder to structured latent
- Diffusion decoder from latent
- Joint training objective
- Controllable generation

**Acceptance Criteria:**
- [ ] Hybrid architecture
- [ ] Generation quality metrics
- [ ] Controllability verification
- [ ] Computational feasibility

---

### Feature 67: Perceiver IO Encoder
**ID:** ARCH-012
**Priority:** Medium
**Complexity:** Medium
**Dependencies:** Feature 61

**Description:**
Handle multi-modal inputs (sequence, structure, metadata) with Perceiver.

**Rationale:**
- Multiple input modalities
- Perceiver handles arbitrary inputs
- Efficient attention mechanism

**Technical Approach:**
- Perceiver encoder architecture
- Cross-attention to latent array
- Multi-modal input handling
- Efficient for long sequences

**Acceptance Criteria:**
- [ ] Perceiver implementation
- [ ] Multi-modal input support
- [ ] Efficiency verification
- [ ] Modality fusion analysis

---

### Feature 68: Mamba State-Space Encoder
**ID:** ARCH-013
**Priority:** High
**Complexity:** High
**Dependencies:** None (alternative to transformer)

**Description:**
Use Mamba (selective state-space model) for efficient long-sequence modeling.

**Rationale:**
- Linear complexity vs quadratic for attention
- Better for very long sequences
- State-of-the-art performance

**Technical Approach:**
- Mamba block implementation
- Selective state-space mechanism
- Hardware-aware implementation
- Integration with VAE

**Acceptance Criteria:**
- [ ] Mamba encoder integration
- [ ] Long sequence handling
- [ ] Speed benchmarks
- [ ] Comparison with transformer

---

### Feature 69: Mixture of Experts VAE
**ID:** ARCH-014
**Priority:** Medium
**Complexity:** High
**Dependencies:** Existing multi-disease framework

**Description:**
Drug-specific expert sub-networks with gating mechanism.

**Rationale:**
- Different drugs have different mechanisms
- Experts specialize per drug class
- Efficient capacity utilization

**Technical Approach:**
- Expert networks per drug class
- Gating network for routing
- Load balancing loss
- Expert utilization analysis

**Acceptance Criteria:**
- [ ] MoE architecture
- [ ] Expert specialization verification
- [ ] Load balancing
- [ ] Per-drug performance

---

### Feature 70: Neural ODE Latent Dynamics
**ID:** ARCH-015
**Priority:** Low
**Complexity:** Very High
**Dependencies:** Existing latent space

**Description:**
Model continuous-time latent evolution for resistance trajectory prediction.

**Rationale:**
- Resistance evolves over time
- Continuous dynamics more realistic
- Trajectory prediction capability

**Technical Approach:**
- Neural ODE latent dynamics
- Adjoint sensitivity for gradients
- Irregular time series handling
- Temporal resistance prediction

**Acceptance Criteria:**
- [ ] Neural ODE integration
- [ ] Trajectory prediction
- [ ] Irregular time handling
- [ ] Computational feasibility

---

## Category 7: Epistasis & Interactions (Features 71-80)

### Feature 71: Tensor Factorization Epistasis
**ID:** EPIST-001
**Priority:** Very High
**Complexity:** High
**Dependencies:** Existing epistasis module

**Description:**
3-way tensor factorization for mutation triplet interactions.

**Rationale:**
- Pairwise epistasis insufficient
- 3-way interactions biologically important
- Tensor methods efficient

**Technical Approach:**
- CP/Tucker decomposition
- Sparse tensor handling
- GPU-accelerated computation
- Interaction significance testing

**Acceptance Criteria:**
- [ ] 3-way tensor implementation
- [ ] Efficient sparse computation
- [ ] Biological validation
- [ ] Integration with analyzer

---

### Feature 72: Graph Neural Network Epistasis
**ID:** EPIST-002
**Priority:** High
**Complexity:** Medium
**Dependencies:** Feature 71

**Description:**
Model mutation co-occurrence as graph with GNN message passing.

**Rationale:**
- Mutations form co-occurrence network
- GNN captures graph structure
- Flexible interaction modeling

**Technical Approach:**
- Mutation co-occurrence graph construction
- GNN encoder for epistasis
- Edge prediction for unknown interactions
- Attention for interaction weights

**Acceptance Criteria:**
- [ ] Epistasis GNN implementation
- [ ] Co-occurrence graph construction
- [ ] Interaction prediction
- [ ] Visualization tools

---

### Feature 73: Attention-based Epistasis
**ID:** EPIST-003
**Priority:** High
**Complexity:** Medium
**Dependencies:** Feature 61 (transformer)

**Description:**
Self-attention weights as epistasis scores for interpretability.

**Rationale:**
- Attention naturally models interactions
- Interpretable by design
- Efficient computation

**Technical Approach:**
- Extract attention weights
- Aggregate multi-head attention
- Position-wise interaction scores
- Attention visualization

**Acceptance Criteria:**
- [ ] Attention extraction pipeline
- [ ] Epistasis interpretation
- [ ] Biological validation
- [ ] Interactive visualization

---

### Feature 74: Evolutionary Epistasis Prior
**ID:** EPIST-004
**Priority:** Medium
**Complexity:** Medium
**Dependencies:** Phylogenetic integration

**Description:**
Use phylogenetic co-evolution as prior for epistasis detection.

**Rationale:**
- Co-evolution indicates interaction
- Prior improves detection power
- Evolutionary validation

**Technical Approach:**
- MI/DCA co-evolution computation
- Prior incorporation in model
- Bayesian epistasis detection
- EVcouplings integration

**Acceptance Criteria:**
- [ ] Co-evolution prior
- [ ] Improved detection
- [ ] Evolutionary validation
- [ ] EVcouplings integration

---

### Feature 75: Fitness Landscape Visualization
**ID:** EPIST-005
**Priority:** High
**Complexity:** Medium
**Dependencies:** All epistasis features

**Description:**
2D projection of epistatic fitness surface for interpretation.

**Rationale:**
- Complex landscapes hard to visualize
- 2D projection aids understanding
- Critical for clinician communication

**Technical Approach:**
- UMAP/t-SNE projection
- Fitness contouring
- Peak/valley identification
- Interactive exploration

**Acceptance Criteria:**
- [ ] Fitness landscape projection
- [ ] Interactive visualization
- [ ] Peak/valley identification
- [ ] Clinical interpretation guide

---

### Feature 76: Synthetic Lethality Prediction
**ID:** EPIST-006
**Priority:** Medium
**Complexity:** Medium
**Dependencies:** Feature 71

**Description:**
Identify mutation combinations lethal to pathogen survival.

**Rationale:**
- Synthetic lethality useful for drug combinations
- Prevents resistance evolution
- Dual-drug targeting

**Technical Approach:**
- Lethal pair detection
- Fitness threshold definition
- Drug pair recommendation
- Experimental validation tracking

**Acceptance Criteria:**
- [ ] Lethal pair prediction
- [ ] Drug combination suggestions
- [ ] Confidence scoring
- [ ] Validation framework

---

### Feature 77: Compensatory Mutation Detection
**ID:** EPIST-007
**Priority:** High
**Complexity:** Medium
**Dependencies:** Feature 71

**Description:**
Identify fitness-restoring secondary mutations.

**Rationale:**
- Resistance often causes fitness cost
- Compensatory mutations restore fitness
- Predicts MDR evolution

**Technical Approach:**
- Cost-compensation modeling
- Temporal mutation ordering
- Reversion prediction
- Clinical monitoring recommendations

**Acceptance Criteria:**
- [ ] Compensatory pair detection
- [ ] Fitness restoration scoring
- [ ] Evolution prediction
- [ ] Clinical alerts

---

### Feature 78: Higher-Order Epistasis (3-way+)
**ID:** EPIST-008
**Priority:** Low
**Complexity:** Very High
**Dependencies:** Feature 71

**Description:**
Model 4-way and higher-order mutation interactions.

**Rationale:**
- Some interactions require 3+ mutations
- Rare but clinically important
- Complete epistasis picture

**Technical Approach:**
- Higher-order tensor methods
- Sparse representation mandatory
- Statistical significance challenges
- Computational constraints

**Acceptance Criteria:**
- [ ] 4-way interaction support
- [ ] Computational feasibility
- [ ] Significance testing
- [ ] Biological validation

---

### Feature 79: Conditional Random Field Epistasis
**ID:** EPIST-009
**Priority:** Low
**Complexity:** High
**Dependencies:** Feature 74

**Description:**
Model Markov blanket dependencies between mutation positions.

**Rationale:**
- CRFs capture local dependencies
- Probabilistic framework
- Inference capabilities

**Technical Approach:**
- CRF model for mutations
- Markov blanket identification
- Inference algorithms
- Structure learning

**Acceptance Criteria:**
- [ ] CRF implementation
- [ ] Inference capabilities
- [ ] Comparison with other methods
- [ ] Biological interpretation

---

### Feature 80: Epistasis-Aware Loss Function
**ID:** EPIST-010
**Priority:** High
**Complexity:** Medium
**Dependencies:** All epistasis features

**Description:**
Loss function that penalizes independent mutation assumption.

**Rationale:**
- Standard losses assume independence
- Epistasis-aware loss improves accuracy
- Better captures biology

**Technical Approach:**
- Interaction-weighted loss
- Epistasis regularization
- Joint prediction loss
- Curriculum with epistasis complexity

**Acceptance Criteria:**
- [ ] Epistasis-aware loss
- [ ] Performance improvement
- [ ] Training stability
- [ ] Integration with all analyzers

---

## Category 8: Clinical Integration (Features 81-90)

### Feature 81: FHIR HL7 Integration
**ID:** CLIN-001
**Priority:** Very High
**Complexity:** High
**Dependencies:** Existing analyzer outputs

**Description:**
Export predictions to FHIR-compliant resources for EHR integration.

**Rationale:**
- Clinical systems use FHIR
- Regulatory requirement
- Seamless workflow integration

**Technical Approach:**
- FHIR resource mapping
- DiagnosticReport resource
- Observation resource for mutations
- FHIR server integration

**Acceptance Criteria:**
- [ ] FHIR R4 compliance
- [ ] DiagnosticReport generation
- [ ] Epic/Cerner compatibility testing
- [ ] HL7 validation

---

### Feature 82: Clinical Decision Support API
**ID:** CLIN-002
**Priority:** Very High
**Complexity:** Medium
**Dependencies:** Feature 81

**Description:**
REST API with treatment recommendations for clinical integration.

**Rationale:**
- API enables integration
- Real-time predictions
- Standard interface

**Technical Approach:**
- FastAPI implementation
- OpenAPI specification
- Authentication/authorization
- Rate limiting and caching

**Acceptance Criteria:**
- [ ] REST API implementation
- [ ] OpenAPI documentation
- [ ] <100ms response time
- [ ] Security audit passed

---

### Feature 83: Resistance Report Generator
**ID:** CLIN-003
**Priority:** High
**Complexity:** Medium
**Dependencies:** Feature 82

**Description:**
Generate PDF/HTML clinical reports similar to Stanford HIVdb.

**Rationale:**
- Clinicians need formatted reports
- Standard report format
- Audit trail

**Technical Approach:**
- Template-based report generation
- PDF/HTML output
- Logo/branding customization
- Version tracking

**Acceptance Criteria:**
- [ ] Report template system
- [ ] PDF generation
- [ ] Clinical validation of format
- [ ] Customization options

---

### Feature 84: Drug-Drug Interaction Checker
**ID:** CLIN-004
**Priority:** High
**Complexity:** Medium
**Dependencies:** Feature 82

**Description:**
Cross-check recommendations with drug interaction databases.

**Rationale:**
- Drug interactions common
- Safety critical
- Comprehensive checking needed

**Technical Approach:**
- DrugBank API integration
- Interaction severity levels
- Alternative suggestions
- Clinical alerts

**Acceptance Criteria:**
- [ ] DrugBank integration
- [ ] Severity classification
- [ ] Alternative drug suggestions
- [ ] Alert system

---

### Feature 85: Genotype-to-Phenotype Mapper
**ID:** CLIN-005
**Priority:** High
**Complexity:** Medium
**Dependencies:** All disease analyzers

**Description:**
Stanford HIVdb-style interpretation algorithms for all diseases.

**Rationale:**
- Standard interpretation format
- Clinician familiarity
- Regulatory alignment

**Technical Approach:**
- Rule-based interpretation layer
- Mutation penalty scoring
- Resistance level classification
- Comments generation

**Acceptance Criteria:**
- [ ] Interpretation algorithm
- [ ] Stanford-compatible output
- [ ] Per-disease customization
- [ ] Expert review

---

### Feature 86: Treatment History Tracker
**ID:** CLIN-006
**Priority:** Medium
**Complexity:** Medium
**Dependencies:** Feature 81

**Description:**
Longitudinal tracking of resistance evolution per patient.

**Rationale:**
- Resistance evolves over treatment
- Historical context important
- Treatment optimization

**Technical Approach:**
- Patient timeline database
- Resistance trajectory visualization
- Treatment response correlation
- Privacy-preserving design

**Acceptance Criteria:**
- [ ] Longitudinal tracking
- [ ] Timeline visualization
- [ ] HIPAA compliance
- [ ] Data retention policies

---

### Feature 87: Point-of-Care Integration
**ID:** CLIN-007
**Priority:** Medium
**Complexity:** High
**Dependencies:** Feature 82

**Description:**
Integration with Cepheid GeneXpert, Abbott, and other POC devices.

**Rationale:**
- POC testing expanding
- Real-time results needed
- Field deployment

**Technical Approach:**
- Device API integration
- Offline capability
- Low-resource optimization
- Result synchronization

**Acceptance Criteria:**
- [ ] Cepheid integration
- [ ] Offline mode
- [ ] Field testing
- [ ] Sync protocols

---

### Feature 88: Surveillance Dashboard
**ID:** CLIN-008
**Priority:** Very High
**Complexity:** High
**Dependencies:** All clinical features

**Description:**
Real-time regional resistance trend monitoring for public health.

**Rationale:**
- Surveillance critical for public health
- Early warning system
- Policy guidance

**Technical Approach:**
- Geographic aggregation
- Temporal trend analysis
- Outbreak detection algorithms
- Public health alerts

**Acceptance Criteria:**
- [ ] Geographic visualization
- [ ] Trend detection
- [ ] Alert system
- [ ] Privacy aggregation

---

### Feature 89: Patient Risk Stratification
**ID:** CLIN-009
**Priority:** Medium
**Complexity:** Medium
**Dependencies:** Feature 86

**Description:**
ML-based treatment failure risk prediction per patient.

**Rationale:**
- Personalized risk assessment
- Resource allocation
- Treatment intensification decisions

**Technical Approach:**
- Risk factor integration
- Survival analysis models
- Risk score calibration
- Clinical action thresholds

**Acceptance Criteria:**
- [ ] Risk model development
- [ ] Clinical validation
- [ ] Calibration verification
- [ ] Action recommendations

---

### Feature 90: Antibiogram Generator
**ID:** CLIN-010
**Priority:** Medium
**Complexity:** Medium
**Dependencies:** Bacterial analyzers

**Description:**
Hospital-specific susceptibility pattern reports.

**Rationale:**
- Empiric therapy guidance
- Hospital infection control
- Regulatory requirement

**Technical Approach:**
- Hospital data aggregation
- Antibiogram format
- Temporal comparison
- Cumulative reports

**Acceptance Criteria:**
- [ ] Standard antibiogram format
- [ ] CLSI/EUCAST alignment
- [ ] Annual report generation
- [ ] Comparison tools

---

## Category 9: Training & Optimization (Features 91-100)

### Feature 91: Sharpness-Aware Minimization (SAM)
**ID:** TRAIN-001
**Priority:** High
**Complexity:** Medium
**Dependencies:** Existing training loop

**Description:**
SAM optimizer for flatter minima and better generalization.

**Rationale:**
- Flatter minima generalize better
- SAM proven effective
- Reduces overfitting

**Technical Approach:**
- SAM optimizer implementation
- Perturbation radius tuning
- ASAM adaptive variant
- Efficiency optimization

**Acceptance Criteria:**
- [ ] SAM implementation
- [ ] Generalization improvement
- [ ] Training stability
- [ ] Computational overhead <2x

---

### Feature 92: Lookahead Optimizer
**ID:** TRAIN-002
**Priority:** Medium
**Complexity:** Low
**Dependencies:** Existing optimizer

**Description:**
Lookahead wrapper for training stability with p-adic loss.

**Rationale:**
- P-adic loss can be unstable
- Lookahead smooths training
- Simple to implement

**Technical Approach:**
- Lookahead wrapper
- k-step lookahead
- Slow weight interpolation
- Base optimizer agnostic

**Acceptance Criteria:**
- [ ] Lookahead implementation
- [ ] Training stability improvement
- [ ] Hyperparameter guidelines
- [ ] Integration with existing optimizers

---

### Feature 93: Gradient Accumulation for Large Batches
**ID:** TRAIN-003
**Priority:** High
**Complexity:** Low
**Dependencies:** Existing training loop

**Description:**
Memory-efficient training with effective large batch sizes.

**Rationale:**
- Large batches improve convergence
- GPU memory limited
- Simple solution

**Technical Approach:**
- Gradient accumulation steps
- Learning rate scaling
- Effective batch size logging
- Mixed precision compatibility

**Acceptance Criteria:**
- [ ] Gradient accumulation
- [ ] Memory reduction verification
- [ ] LR scaling guidelines
- [ ] Multi-GPU support

---

### Feature 94: Mixed Precision Training
**ID:** TRAIN-004
**Priority:** High
**Complexity:** Medium
**Dependencies:** Existing training loop

**Description:**
FP16/BF16 training for faster training with maintained accuracy.

**Rationale:**
- 2x+ speedup possible
- Modern GPUs optimized for FP16
- Minimal accuracy loss

**Technical Approach:**
- Automatic mixed precision (AMP)
- Loss scaling
- BF16 where available
- Numerical stability checks

**Acceptance Criteria:**
- [ ] AMP integration
- [ ] Speedup measurement
- [ ] Accuracy parity verification
- [ ] Numerical stability

---

### Feature 95: Stochastic Weight Averaging (SWA)
**ID:** TRAIN-005
**Priority:** Medium
**Complexity:** Low
**Dependencies:** Existing training loop

**Description:**
Ensemble without extra models via weight averaging.

**Rationale:**
- Better generalization
- No inference overhead
- Simple implementation

**Technical Approach:**
- Weight averaging schedule
- SWA learning rate
- BatchNorm update post-SWA
- Multi-model SWA option

**Acceptance Criteria:**
- [ ] SWA implementation
- [ ] Generalization improvement
- [ ] BatchNorm handling
- [ ] Schedule optimization

---

### Feature 96: Learning Rate Range Test
**ID:** TRAIN-006
**Priority:** Medium
**Complexity:** Low
**Dependencies:** Training infrastructure

**Description:**
Automatic optimal learning rate finding.

**Rationale:**
- LR critical hyperparameter
- Automated finding saves time
- Reproducible selection

**Technical Approach:**
- LR range test implementation
- Loss curve analysis
- Optimal LR suggestion
- Integration with config system

**Acceptance Criteria:**
- [ ] LR range test
- [ ] Automatic suggestion
- [ ] Visualization
- [ ] Config integration

---

### Feature 97: Cyclical Learning Rates
**ID:** TRAIN-007
**Priority:** Medium
**Complexity:** Low
**Dependencies:** Feature 96

**Description:**
Cyclical LR schedules to escape local minima.

**Rationale:**
- Can escape local minima
- Super-convergence possible
- Well-studied technique

**Technical Approach:**
- Triangular cyclical LR
- Cosine annealing with restarts
- OneCycleLR integration
- Cycle length optimization

**Acceptance Criteria:**
- [ ] Cyclical LR implementation
- [ ] Performance comparison
- [ ] Cycle length guidelines
- [ ] Warmup integration

---

### Feature 98: Knowledge Distillation Compression
**ID:** TRAIN-008
**Priority:** High
**Complexity:** Medium
**Dependencies:** Trained models

**Description:**
Deploy lightweight distilled models for inference.

**Rationale:**
- Production requires efficiency
- Distillation preserves performance
- Edge deployment possible

**Technical Approach:**
- Teacher-student training
- Soft label distillation
- Feature matching
- Progressive distillation

**Acceptance Criteria:**
- [ ] Distillation pipeline
- [ ] Performance retention (>95%)
- [ ] Model size reduction (>4x)
- [ ] Inference speedup

---

### Feature 99: Neural Architecture Search
**ID:** TRAIN-009
**Priority:** Low
**Complexity:** Very High
**Dependencies:** All architecture options

**Description:**
AutoML for disease-specific optimal architectures.

**Rationale:**
- Optimal architecture varies by disease
- Manual search inefficient
- AutoML can find better architectures

**Technical Approach:**
- Search space definition
- DARTS or evolution-based search
- Multi-objective (accuracy + efficiency)
- Transfer from searched architectures

**Acceptance Criteria:**
- [ ] NAS framework
- [ ] Search space coverage
- [ ] Found architecture evaluation
- [ ] Computational budget management

---

### Feature 100: Federated Learning
**ID:** TRAIN-010
**Priority:** Very High
**Complexity:** Very High
**Dependencies:** All features

**Description:**
Privacy-preserving multi-hospital training without data sharing.

**Rationale:**
- Hospital data cannot be shared
- Combined data improves models
- Privacy regulatory compliance

**Technical Approach:**
- Federated averaging
- Secure aggregation
- Differential privacy
- Heterogeneous data handling

**Acceptance Criteria:**
- [ ] Federated learning framework
- [ ] Privacy guarantees (DP budget)
- [ ] Performance vs centralized
- [ ] Multi-site deployment

---

## Appendix: Feature Cross-Reference

### By Complexity
- **Low:** 22, 24, 25, 37, 38, 53, 59, 92, 93, 95, 96, 97
- **Medium:** 1, 2, 3, 4, 9, 10, 13, 14, 15, 16, 17, 23, 27, 28, 29, 33, 34, 35, 36, 39, 41, 42, 43, 47, 50, 52, 58, 67, 72, 73, 74, 75, 76, 77, 80, 82, 83, 84, 85, 86, 89, 90, 91, 94, 98
- **High:** 5, 6, 8, 11, 12, 18, 19, 26, 30, 31, 40, 45, 46, 48, 49, 51, 55, 56, 57, 61, 62, 63, 68, 69, 71, 79, 81, 87, 88, 100
- **Very High:** 7, 20, 21, 32, 64, 65, 66, 70, 78, 99

### By Priority
- **Very High:** 36, 46, 51, 56, 71, 81, 82, 88, 100
- **High:** 1, 2, 9, 10, 11, 12, 13, 16, 26, 27, 29, 37, 38, 39, 43, 48, 50, 52, 55, 57, 58, 61, 68, 72, 73, 75, 77, 80, 83, 84, 85, 91, 93, 94, 98
- **Medium:** 3, 4, 5, 6, 8, 14, 15, 17, 18, 19, 21, 23, 25, 28, 30, 31, 33, 34, 40, 41, 42, 44, 47, 53, 54, 59, 62, 64, 66, 67, 69, 74, 76, 86, 87, 89, 90, 92, 95, 96, 97
- **Low:** 7, 20, 22, 24, 32, 35, 60, 63, 65, 70, 78, 79, 99
